Press Releases

Date Title  
Toggle Summary Natera Announces Second Quarter 2020 Earnings Conference Call
SAN CARLOS, Calif. , July 29, 2020 /PRNewswire/ -- Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that it will release results for its second quarter ended June 30, 2020 , after the market close on August 5, 2020 .
Toggle Summary Natera Recognized as a 'Force for Change' by Leading Women Entrepreneurs (LWE)
SAN CARLOS, Calif. , July 14, 2020 /PRNewswire/ --  Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, has received the Force for Change Illuminator award from LWE, accepted by Sheetal Parmar , Natera's VP of Medical Affairs.
Toggle Summary Natera Expands Lab Footprint With State-Of-The-Art Facility in Austin, Texas
Grows capacity to process up to three million tests annually SAN CARLOS, Calif. , June 22, 2020 /PRNewswire/ --  Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, is pleased to announce the expansion of its laboratory facility in Austin, Texas , supporting greater
Toggle Summary Natera Announces First Patient Enrollments in Both CIRCULATE-Japan and BESPOKE CRC Trials Using Signatera™ MRD Testing
Two large-scale studies evaluating use of Signatera in colorectal cancer gain early momentum SAN CARLOS, Calif. , June 18, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that enrollment has begun in the CIRCULATE-Japan and
Toggle Summary Natera Files Patent Suit Against Progenity, Inc.
SAN CARLOS, Calif. , June 17, 2020 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a global leader in cell-free DNA testing, filed suit today against Progenity, Inc. for infringing six patents: U.S. Patents  9,228,234; 9,424,392; 10,227,652; 10,240,202; 10,266,893; and 10,522,242 (the "Asserted
Toggle Summary Natera Launches Quantification Technique to Enhance Prospera™ Test Precision; Initiates PEDAL Study for New Insights
Quantifying background cfDNA increases accuracy of dd-cfDNA testing SAN CARLOS, Calif. , June 1, 2020 /PRNewswire/ --   Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, is pleased to announce the launch of a novel technique to enhance results from the Prospera
Toggle Summary Natera Announces New Prospera™ Data at ATC Showcasing Innovation in Cell-Free DNA
New research on background cell-free DNA to refine transplant rejection risk SAN CARLOS, Calif. , May 26, 2020 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will present new data on its Prospera donor-derived cell-free DNA
Toggle Summary Natera Announces New Data at ASCO Highlighting Utility of Personalized MRD Monitoring
Results from the first large, real-world study in 535 gastrointestinal (GI) cancer patients using Signatera™ MRD testing New data using Signatera to monitor treatment response with an immunotherapy-based regimen in hepatocellular carcinoma SAN CARLOS, Calif.
Toggle Summary Natera and Illumina Settle Patent Dispute
SAN CARLOS, Calif. and SAN DIEGO , May 18, 2020 /PRNewswire/ --  Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, and Illumina Inc. (NASDAQ: ILMN), a global leader in next-generation sequencing platforms, today announced that they have settled their patent
Toggle Summary Natera to Present at the UBS Virtual Global Healthcare Conference
SAN CARLOS, Calif. , May 13, 2020 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that it will webcast a live presentation at the UBS Virtual Global Healthcare Conference on Monday, May 18, 2020 at 12:50 p.m. PT ( 3:50 p.m. ET ).

Footer disclaimer

Footer disclaimer

© Natera 2020. All Rights Reserved. The tests described on this site were developed by Natera, Inc. a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). The tests have not been cleared or approved by the U.S. Food and Drug Administration (FDA). Although FDA does not currently clear or approve laboratory-developed tests in the U.S., certification of the laboratory is required under CLIA to ensure the quality and validity of the tests.